Experimental Eye Research, Год журнала: 2024, Номер 249, С. 110144 - 110144
Опубликована: Ноя. 1, 2024
Язык: Английский
Molecules, Год журнала: 2025, Номер 30(6), С. 1210 - 1210
Опубликована: Март 8, 2025
Rare earth metal nanoparticles, some of which are already widely used in medicine, growing interest the modern scientific community. One promising rare metals for biomedical applications is cerium, specifically its oxide form, characterized by a higher level stability and safety. According to number studies, cerium dioxide has wide range biological effects (regenerative, antimicrobial, antioxidant, antitumor), justifies potential application medicine. However, these their intensity vary significantly across studies. Since was it can be assumed that not only chemical formula important, but also physicochemical parameters nanoparticles obtained, consequently methods synthesis modification with use excipients. In this review, we considered possibilities using excipients (polyacrylate, polyvinylpyrrolidone, dextran, hyaluronic acid, chitosan, polycarboxylic acids, lecithin, phosphatidylcholine) context preserving properties, as well degree study combinations from point view prospect creating drugs based on applications.
Язык: Английский
Процитировано
0
Pharmaceutics, Год журнала: 2025, Номер 17(3), С. 394 - 394
Опубликована: Март 20, 2025
In addition to classic small-molecule drugs and modern protein-based biologics, an intriguing class of medicines is the therapeutic oligonucleotides. Most approved in this category are antisense oligomers or those acting via RNA interference, both which use base hybridization. Aptamers, also known as chemical antibodies form a smaller, yet equally interesting group oligonucleotides that can recognize wide range molecular targets. Despite their high potential, only two aptamers have been date, pegaptanib (MacugenTM) avacincaptad pegol (IzervayTM), for treatment age-related macular degeneration (AMD). Targeting vascular endothelial growth factor (VEGF), plays important role pathogenesis many eye diseases, emerged first anti-VEGF agent was used various indications, further inspiring development other therapies. review, we summarize history aptamer medicine, pegaptanib. We describe its chemistry track from earliest stages preclinical phase, clinical trials, eventual regulatory approval. Additionally, evaluate position among agents provide comprehensive overview pegaptanib’s efficacy, safety, cost-effectiveness, comparing these aspects with monoclonal similar bevacizumab ranibizumab.
Язык: Английский
Процитировано
0
Journal of drug targeting, Год журнала: 2024, Номер unknown, С. 1 - 49
Опубликована: Дек. 18, 2024
Nanomedicine offers a promising avenue for improving retinal drug delivery, effectively addressing challenges associated with ocular diseases like age-related macular degeneration and diabetic retinopathy. Nanoparticles, their submicron size customizable surface properties, enable enhanced permeability retention within tissues, supporting sustained release minimizing systemic side effects. Nanostructured scaffolds further provide supportive environment cell growth tissue regeneration, crucial treating degenerative conditions. Additionally, advanced nanodevices facilitate real-time monitoring controlled release, marking significant progress in therapy. This study reviews recent advancements nanomedicine critically analyzing design innovations, therapeutic benefits, limitations of these systems. By advancing nanotechnology integration therapies, this field holds strong potential overcoming current barriers, ultimately patient outcomes quality life.
Язык: Английский
Процитировано
1
Experimental Eye Research, Год журнала: 2024, Номер 249, С. 110144 - 110144
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
0